Acarix Ab · OMXSTO:ACARIX
Acarix Ab — Q2 2025 Earnings Presentation
30 slides from Acarix Ab's earnings presentation, Aug 21, 2025
Slide 1: Acarix Q2 2025: Transforming Early Cardiac Diagnostics
Transforming Early Cardiac Diagnostics Acarix Q2 2025 Aamir Mahmood President & CEO 08/21/25
Slide 2: The CADScor System
The CADScor®System Transforming Early Cardiac Diagnostics with Rapid Assessment A rapid, point of care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to calculate a patient specific CAD risk score Quickly and easily risk-stratify significant coronary artery
Slide 3: Executive Summary, Q2 Highlights, Q2 Financials
Executive Q2 Q2 Summary Highlights Financials 3
Slide 4: Executive Summary
q aig? Executive Summary
Slide 5: Continuous Expansion and Progress in Q2
Continuous Expansion and Progress in Q2 Growth in U.S. Market Performance ● Delivered 19 CADScor® Systems in the U.S., a 27% increase YoY; all systems consigned and installed at customer sites ● Patch sales rose 11% in the U.S. (1,400 units vs. 1,260 YoY), reflecting continued clinical adoption desp
Slide 6: Aamir Mahmood CEO message
As we conclude the second quarter of 2025, I want to highlight Acarix’s progress, particularly our first fixed-rate reimbursement in the U.S. at $300 per test and a second agreement shortly after, expanding coverage to more than 500,000 lives. These milestones signal the start of broader access and
Slide 7: Q2 Highlights
Q2 Highlights aig?
Slide 8: Peer-Reviewed U.S. Study Validates Cost Savings of CADScor System
Peer-Reviewed U.S. Study Validates Cost Savings of CADScor® System ● In June 2025, a peer-reviewed study published in PharmacoEconomics – Open demonstrated that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. ● The st
Slide 9: Expansion into MENA Region: First Major Order Secured
Expansion into MENA Region: First Major Order Secured ● First order in the MENA region secured in July 2025, valued at SEK 1.35 million, from a leading regional distributor—marking Acarix’s official entry into one of the world’s most dynamic healthcare markets ● This milestone underscores global dem
Slide 10: Establishing a Scalable Reimbursement Framework
Establishing a Scalable Reimbursement Framework ● Secured first fixed-rate reimbursement of $300 per test from a regional Third Party Administrator (TPA) in Oklahoma during Q2—marking a key milestone in market access. ● Second payer added post-quarter, expanding coverage to 500,000+ lives across fou
Slide 11: 0716T Private Clinic Reimbursement
0716T Private Clinic Reimbursement Removed 0716T off non- Removed 0716T off non- Federal, GA, LA, IL, AZ covered list covered list Avg payment Avg payment Avg payment Average $230 $302 $339 Reimbursement $387 Federal Avg payment Avg payment Avg payment $403 $750 $300 Q2 2025 showing consistent reimb
Slide 12: U.S. Performance Trial
U.S. Performance Trial ● Overview: Formalized an agreement to support an investigator-initiated clinical study with the largest health system in Oklahoma City. ● Objective: To demonstrate that the sensitivity of the CADScor System in low to intermediate-risk U.S. patients referred for coronary CT an
Slide 13: U.S. Performance Trial cont.
U.S. Performance Trial cont. ● U.C. Davis Trial ○ Enrollment is approaching 100 patients, marking steady progress and consistent enrollment performance. ○ An abstract is currently under review by the American Heart Association for potential inclusion in the November 2025 AHA Scientific Sessions in N
Slide 14: Q2 Efficiency Gains Driving Scalable Growth
Q2 Efficiency Gains Driving Scalable Growth ● Operating costs decreased by 24% YoY in Q2, totaling SEK 13.9M — a clear result of disciplined cost containment and improved operational processes ● Net loss improved by 23%, narrowing from SEK -16.7M to SEK -12.9M YoY, underscoring the scalability and r
Slide 15: LinkedIn - Quarterly Overview
Linkedin - Quarterly Overview Channel KPIs 212 31,826 1,307 31 40 4.33% Engagement New Followers Impressions Reactions Comments Reposts Rate Channel Insights ● Engagement rate rose to 4.33%, above industry (medical devices) avg. of 2.8%. ● Growing engagement signals content is resonating better with
Slide 16: X - Quarterly Overview
X - Quarterly Overview Channel KPIs 12 7,433 970 13% 42 New Followers Impressions Engagement Profile Visits Engagements Rate Channel Insights ● Engagement rate rose to 13%, well above industry (medical devices) avg. of 1.3%, indicating strong relevance among those who saw our posts ● Rising engageme
Slide 17: ACC.25 Paid Media Pilot - Proof of Digital Impact
ACC.25 Paid Media Pilot - Proof of Digital Impact Strategic Win ● First end-to-end digital tracking, enabling smarter, scalable U.S. marketing. ● Confirmed paid media can efficiently reach and convert the right cardiology audience. Performance Highlights: ● 978K impressions, 4.97K site clicks, and 4
Slide 18: Q2 Financials
q aig? Q2 Financials
Slide 19: Q2 2025 Financial Highlights
Q2 2025 Financial Highlights U.S. CADScor U.S. Patch Operating Systems Sales Costs Delivered 27% 11% 24% YoY Quarterly YoY Quarterly YoY Quarterly Our financial discipline remains a core strength… These are not just financial metrics; they are clear indicators that our operating model is scalable, a
Slide 20: Q2 Profit/Loss Statement
Q2 Profit/Loss Statement ● Sales Performance: Revenue reached SEK 1,140 thousand in Q2 2025, in line with expectations following the strategic divestment in the EU, a sharpened focus on the U.S. market, and the decision to consign rather than sell the majority of CADScor units. The U.S. market accou
Slide 21: CADScor Placements Drive Increased Patch Usage
Continued Momentum: CADScor® Placements Drive Increased Patch Usage U.S. CADScor System Installations U.S. Acoustic Patch Sales ● In Q2, our leading customer used an average of 5.3 patches per day for patient assessments. 21
Slide 22: Wider Clinical Adoption Across Key Disciplines
Wider Clinical Adoption Across Key Disciplines U.S. CADScor System Installations* ● Cardiology led with notable growth, and primary care maintained a positive trajectory. ● Continued focus on increasing usage ER/urgent care. *Numbers are accumulated 22
Slide 23: Q2 U.S. CADScor Units Installed
Q2 U.S. CADScor Units Installed U.S. CADScor Units 19 15 +27% Q2 2024 Q2 2025 ● A total of 19 CADScor Systems were delivered, an increase of 27%. All 19 systems were consigned and installed at customer sites within the US market. 23
Slide 24: Q2 U.S. Patch Sales
Q2 U.S. Patch Sales U.S. Patch Sales (units) 1,400 +11% 1,260 Q2 2024 Q2 2025 ● In the U.S., patch sales amounted 1,400, an increase of 11% compared to the same quarter in 2024. 24
Slide 25: Q2 Global Gross Margin
Q2 Global Gross Margin Gross Margin 91% 94% +3 point Q2 2024 Q2 2025 ● The gross margin on sales remained strong at 94%, maintaining a 3 percentage point improvement over the same quarter of the previous year. 25
Slide 26: Continued Cost Saving Initiatives
Continued Cost Saving Initiatives OPEX Reduction kSEK 18,368 13,915 -24% Q2 2024 Q2 2025 ● Operating expenses for the period totaled SEK -13,915 thousand, representing a 24% decrease compared to SEK 18,368 thousand in the same period of 2024. This reduction underscores the company's ongoing cost-sav
Slide 27: Q2 Net Loss
Q2 Net Loss Net Loss kSEK -16,661 -12,863 -23% Q2 2024 Q2 2025 ● The net loss for the period amounted to SEK -12,863 thousand, representing an improvement of SEK 3,798 thousand, or 23%, compared to the same period last year. 27
Slide 28: Monthly Burn Rate
Monthly Burn Rate Monthly Burn Rate kSEK -5,100 -4,200 -18% Q2 2024 Q2 2025 ● Q2 2025 monthly burn rate was down 18 % vs Q2 2024. 28
Slide 29: Key Go-Forward Objectives
Key Go-Forward Objectives ● The GEO-MED partnership presents an exciting opportunity, and while immediate sales may not occur, we remain confident about achieving sales within the next 3 to 6 months. ● Clinical Trials: ○ Update: Systematic review of clinical trials has been completed and submitted f
Slide 30: Thank You!
Transforming Early Cardiac Diagnostics Thank You! 30